{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:27:30Z","timestamp":1763036850872,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.bcmd.2014.07.013","type":"journal-article","created":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T14:01:40Z","timestamp":1408111300000},"page":"97-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"54","author":[{"given":"Doralina do Amaral","family":"Rabello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Roberto","family":"Lucena-Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Carvalho Rocha","family":"Alves-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vin\u00edcius Burnett Aboud Souza","family":"da Eira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Catarina Cals","family":"de Vasconcellos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1bio Morato","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1567-4086","authenticated-orcid":false,"given":"Eduardo Magalhaes","family":"Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Saldanha-Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9644-7098","authenticated-orcid":false,"given":"F\u00e1bio","family":"Pittella Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2014.07.013_bb0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2009-08-207126","article-title":"How I treat CLL up front","volume":"115","author":"Gribben","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0010","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2014Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","article-title":"ZAP-70 expression and prognosis in chronic lymphocytic leukaemia","volume":"363","author":"Orchard","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0020","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(08)60456-0","article-title":"Chronic lymphocytic leukaemia","volume":"371","author":"Dighiero","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0025","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3324\/haematol.2012.069369","article-title":"Clinical implications of the molecular genetics of chronic lymphocytic leukemia","volume":"98","author":"Foa","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbcan.2010.10.002","article-title":"Histone lysine methylation and demethylation pathways in cancer","volume":"1815","author":"Varier","year":"2011","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0035","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4161\/cbt.3.10.1137","article-title":"Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL)","volume":"3","author":"Kn","year":"2004","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcmd.2014.07.013_bb0040","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1038\/sj.onc.1204639","article-title":"Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins","volume":"20","author":"Ayton","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccr.2011.06.016","article-title":"Coordinated regulation of polycomb group complexes through microRNAs in cancer","volume":"20","author":"Cao","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0050","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.cell.2007.02.009","article-title":"Genome regulation by polycomb and trithorax proteins","volume":"128","author":"Schuettengruber","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0055","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ng1950","article-title":"Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer","volume":"39","author":"Schlesinger","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2014.07.013_bb0060","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0065","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2011-11-394932","article-title":"Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia","volume":"120","author":"Tanaka","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0070","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0075","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1258\/ebm.2012.012075","article-title":"Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia","volume":"237","author":"Chen","year":"2012","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.bcmd.2014.07.013_bb0080","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/leu.2013.80","article-title":"Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies","volume":"27","author":"Khan","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0085","first-page":"1640","article-title":"The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL","volume":"8","author":"Matutes","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V98.1.29","article-title":"Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy","volume":"98","author":"Rawstron","year":"2001","journal-title":"Blood"},{"year":"2009","author":"International Standing Committee on Human Cytogenetic N","series-title":"ISCN 2009: An International System for Human Cytogenetic Nomenclature","key":"10.1016\/j.bcmd.2014.07.013_bb0095"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0100","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcmd.2014.07.013_bb0105","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-05-1531","article-title":"ZAP-70 expression in normal pro\/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia","volume":"12","author":"Crespo","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcmd.2014.07.013_bb0110","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1182\/blood-2005-04-1718","article-title":"ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)","volume":"107","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0115","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.2011.39.3090","article-title":"Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia","volume":"30","author":"Claus","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2014.07.013_bb0120","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-10-2156","article-title":"Aberrations of EZH2 in cancer","volume":"17","author":"Chase","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcmd.2014.07.013_bb0125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molcel.2008.11.004","article-title":"Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms","volume":"32","author":"Margueron","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-9-108","article-title":"MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1\u03b1\/HIF-1\u03b2","volume":"9","author":"Cao","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcmd.2014.07.013_bb0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2119\/molmed.2013.00005","article-title":"Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia","volume":"19","author":"Papakonstantinou","year":"2013","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcmd.2014.07.013_bb0140","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stem.2010.08.002","article-title":"Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer","volume":"7","author":"Sauvageau","year":"2010","journal-title":"Cell Stem Cell"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614000928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614000928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:30:47Z","timestamp":1761049847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979614000928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1079979614000928"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.07.013","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}